MDMA chemical structureEcstasy commonly appears in a tablet form, usually imprinted with a monogram.The title screen to Peter Jennings - Ecstasy Rising
Find information on thousands of medical conditions and prescription drugs.

MDMA

MDMA (3,4-methylenedioxymethamphetamine), most commonly known today by the street name ecstasy, is a synthetic entactogen of the phenethylamine family whose primary effect is to stimulate the secretion of and inhibit the re-uptake of large amounts of serotonin as well as dopamine and noradrenaline in the brain, causing a general sense of openness, empathy, energy, euphoria, and well-being. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
Macrodantin
Maprotiline
Marcaine
Marezine
Marijuana
Marinol
Marplan
Matulane
Maxair
Maxalt
Maxolon
MDMA
Measurin
Mebendazole
Mebendazole
Meclofenoxate
Medrol
Mefenamic acid
Mefloquine
Melagatran
Melarsoprol
Meloxicam
Melphalan
Memantine
Metadate
Metamfetamine
Metamizole sodium
Metandienone
Metaxalone
Metenolone
Metformin
Methadone
Methamphetamine
Methaqualone
Metharbital
Methcathinone
Methenamine
Methionine
Methocarbamol
Methohexital
Methotrexate
Methotrexate
Methoxsalen
Methylcellulose
Methyldopa
Methylergometrine
Methylin
Methylphenidate
Methylphenobarbital
Methylprednisolone
Methyltestosterone
Methysergide
Metiamide
Metoclopramide
Metohexal
Metoprolol
Metrogel
Metronidazole
Metyrapone
Mobic
Moclobemide
Modafinil
Modicon
Monopril
Montelukast
Motrin
Moxidectin
Moxifloxacin
Moxonidine
MS Contin
Mucinex
Mucomyst
Mupirocin
Mupirocin
Muse
Mycitracin
Mycostatin
Myfortic
Mykacet
Mykinac
Myleran
Mylotarg
Mysoline
Phentermine
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Tactile sensations are enhanced for some users, making general physical contact with others more pleasurable; but, contrary to popular mythology it generally does not have aphrodisiac effects. Its ability to facilitate self-examination with reduced fear has proven useful in some therapeutic settings, leading to its 2001 approval by the United States FDA for testing in patients with post-traumatic stress disorder.

Acute dehydration is a risk among users who are highly physically active and forget to drink water, as the drug may mask one's normal sense of exhaustion and thirst. Also the opposite, "water intoxication" resulting in acute hyponatremia has been reported. By far the biggest danger comes from the fact that other, more dangerous chemicals (such as PMA, or methamphetamine) are either added to ecstasy tablets, or more often simply sold as ecstasy. Long-term effects in humans are largely unknown and the subject of much controversy —particularly with regard to the risks of severe long-term depression as a result of a reduction in the natural production of serotonin.

MDMA is also known by many other street names, including Adam, Beans, Biscuits, Candy, E, Eccies, Googs, Jack and Jills, MaDMAn, Mollies, Pills, Rolls, Scoobies, Smarties, Tabs, Thizz, Vitamin E, Vitamin X, X, XTC, Yaotou (in East Asia), and Yokes.

History

A patent for MDMA was originally filed on Christmas eve 1912 by the German pharmaceutical company Merck, and granted two years later (to the day). At the time, MDMA was not known to be a drug in its own right; rather, it was patented as an intermediate chemical used in the synthesis of a styptic (a drug intended to control bleeding from wounds.) Over half a century would pass before the first known ingestion of MDMA by humans.

Contrary to many rumours, the drug was never used as an appetite suppressant or as a stimulant for armed forces during wartime. (This was in fact methamphetamine.) The U.S. Army did, however, do lethal dose studies of it and several other compounds in the mid-1950's. It was given the name EA-1475, with the EA standing for Edgewood Arsenal. The results of these studies were not declassified until 1969. MDMA was first brought to public attention through Dr. Alexander Shulgin in the 1960s who recommended it for use in certain therapy sessions, naming the drug 'window' (he discovered it while searching for compounds that might have a similar psychoactive effect as other compounds contained in nutmeg). It was widely used therapeutically by US psychotherapists because of its empathogenic effects until its criminalization in the late 1980s. The drug was hailed as a miracle by therapists and counselors who claimed couples could have six months worth of progress in one use of the drug, and soldiers returning from the Vietnam war could overcome their PTSD sometimes more effectively than talk or group therapy. A small number of therapists continue to use it in their practices today. (See below for 2001 FDA approval and DEA licensing for use in patients with post-traumatic stress disorder.)

Read more at Wikipedia.org


[List your site here Free!]


Psychedelic revival: research on forbidden drugs
From Reason, 6/1/05 by Jacob Sullum

BEFORE HE became notorious as an apostle of chemically catalyzed enlightenment and lost his job at Harvard, Timothy Leary investigated the use of psilocybin and LSD in rehabilitating alcoholics and convicts. Such psychotherapeutic applications, explored in more than 1,000 papers and dozens of books in the 1950s and '60s, were largely forgotten in the hysteria prompted by the widespread recreational use of psychedelics. LSD and similar drugs were soon banned, putting a stop to studies of their benefits.

Four decades later, psychedelic research is returning to Harvard, where psychiatrist John Halpern plans to give MDMA (a.k.a. Ecstasy) to late-stage cancer patients to relieve their anxiety and to help them come to terms with death. The study was approved by the Food and Drug Administration in December, and the Drug Enforcement Administration was expected to issue the required federal license after a March visit to the research site.

Halpern's work is part of a recent resurgence in psychedelic research prompted largely by the Multidisciplinary Association for Psychedelic Studies, an organization dedicated to exploring the benefits of substances neglected because of the war on drugs. Other projects supported by the group include psychiatrist Charles Grub's psilocybin research with terminal cancer patients at UCLA; Charleston, South Carolina, psychiatrist Michael Mitohefer's study of MDMA as a treatment for posttraumatic stress disorder; and University of Arizona at Tucson psychiatrist Francisco Moreno's study of psilocybin as a treatment for obsessive compulsive disorder. Projects in development or awaiting approval include MDMA studies in Spain and Israel, a Russian study of ketamine as a treatment for heroin addicts, and a U.S. study of LSD for relieving anxiety in terminal cancer patients.

From a scientific perspective, the remarkable thing is not that such research is finally occurring but that it was interrupted for so long. As Leary observed, "psychedelic drugs cause panic and temporary insanity in people who have not taken them."

COPYRIGHT 2005 Reason Foundation
COPYRIGHT 2005 Gale Group

Return to MDMA
Home Contact Resources Exchange Links ebay